Previous close | 2.5650 |
Open | 2.5550 |
Bid | 2.5650 x N/A |
Ask | 2.5900 x N/A |
Day's range | 2.5550 - 2.5600 |
52-week range | 2.5550 - 3.3110 |
Volume | |
Avg. volume | 0 |
Market cap | 207.229M |
Beta (5Y monthly) | 0.71 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
MARSEILLE, France, June 18, 2024--Regulatory News: Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") releases its total number of shares outstanding as well as its voting rights as at June 10, 2024:
MARSEILLE, France, June 17, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced today that updated efficacy and safety results from the dose-escalation part of the Phase 1/2 study with SAR443579/IPH6101 (SAR'579), an investigational CD123 targeting NKp46/CD16-based Natural Killer Cell Engager (NKCE), from a joint research collaboration between Innate Pharma and Sanofi and ANKET® platform lead asset, were shared in an oral presentation
MARSEILLE, France, June 04, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced favorable results from the Phase 2 TELLOMAK study with lacutamab in mycosis fungoides (MF). The results were presented at the ASCO 2024 Annual Meeting, in Chicago, Illinois.